PODD·Insulet Corporation

Insulet Corporation is a medical device company focused on developing and manufacturing innovative insulin delivery systems for individuals with insulin-dependent diabetes, primarily through its Omnipod platform. Operating within the Healthcare sector's Medical Devices industry, the company's core products include the automated Omnipod 5 system and the Omnipod DASH system, alongside manufacturing pods for Amgen's Neulasta Onpro kit. In the most recent reported quarters, Insulet demonstrated a mixed performance against analyst expectations. For Q4 2025, the company reported EPS of $1.55, exceeding the estimate of $1.17827, and revenue of $783.8 million, surpassing the estimate of $714.3266 million. However, in Q1 2026, while EPS of $1.42 beat the estimate of $1.1907, revenue of $761.7 million fell short of the $730.10084 million estimate. This pattern suggests a recent trend of EPS beats alongside occasional revenue misses. Historically, Insulet has shown a trajectory of growth, with notable beats in EPS in Q4 2025 and Q1 2026, although revenue performance has been less consistent, missing estimates in Q1 2026. Recent news highlights analyst optimism regarding Insulet's long-term growth, with Benchmark initiating coverage with a "Buy" rating and a $250 price target, citing strategic international expansion in the Middle East and North Africa. Despite strong Q1 revenue growth driven by Omnipod 5 adoption, concerns about the growth trajectory have led some analysts, like Goldman Sachs, to reduce price targets. Investors will be watching for continued adoption of the Omnipod 5, particularly in the type 2 diabetes segment, and how the company navigates seasonality and insurance deductible resets in its upcoming quarterly reports, as well as the impact of its international expansion efforts on overall growth and profitability.